AAV cDNA gene therapy - Sangamo Therapeutics

Drug Profile

AAV cDNA gene therapy - Sangamo Therapeutics

Alternative Names: AAV cDNA hF8 gene therapy; AAV cDNA human Factor 8 gene therapy; SB-525

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 05 Jan 2017 US FDA approves IND application for SB 525 in haemophilia A
  • 30 Nov 2016 Preclinical data presented at the 58TH Annual Meeting of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top